Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate 3-month formulation relapse prevention study in schizophrenia
2011-004676-11Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing PP3M with Placebo (2 arms). Primary endpoint: Time to first relapse event. Started Mar 2017; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2011-004676-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004676-11.